liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Activation of VPAC(1) receptors aggravates early atherosclerosis in hypercholesterolemic apolipoprotein E-deficient mice
Karolinska University Hospital Solna.
Karolinska University Hospital Solna.
Karolinska University Hospital Solna.
Karolinska University Hospital Solna.
Show others and affiliations
2010 (English)In: Biochemical and Biophysical Research Communications - BBRC, ISSN 0006-291X, E-ISSN 1090-2104, Vol. 402, no 3, 471-476 p.Article in journal (Refereed) Published
Abstract [en]

Objective Vasoactive intestinal peptide (VIP) is a 28-amino acid peptide widely expressed in the body and binding three types of receptors VPAC(1)-R, VPAC(2)-R and PAC(1)-R Based on beneficial effects of VIP and VPAC(1)-R agonists in mouse models of several chronic inflammatory disorders, we hypothesized that activation of VIP receptors would prevent atherosclerosis development in apolipoprotein E-deficient mice Methods and results Contrary to our hypothesis, administration of a VPAC(1)-R agonist. (Ala(11 22,28))-VIP aggravated atherosclerotic lesion development in the aortic root of these mice compared to control mice This was accompanied by a significant Increase in the expression of MHC class II protein I-A(b), and suggests enhanced inflammatory activity in the vessel wall The amount of macrophage-specific CD68 staining as well as serum cholesterol and triglyceride levels did not change as a result of the (Ala(11 22,28))-VIP treatment, i e the treatment resulted in significant changes in lipid accumulation in the lesions without changing the number of macrophages or systemic lipid levels Interestingly, administration of VIP did not alter the course of the disease. Conclusion: Despite beneficial effects in murine models of several inflammatory disorders, VPAC(1)-R activation aggravates atherosclerotic lesion formation in apolipoprotein E-deficient mice through enhanced inflammatory activity in the vessel wall

Place, publisher, year, edition, pages
Elsevier Science B.V., Amsterdam , 2010. Vol. 402, no 3, 471-476 p.
Keyword [en]
Vasoactive intestinal peptide (VIP); (Ala(11 22, 28))-VIP; VIP/pituitary adenylate cyclase-activating peptide receptor (VPAC-R); Atherosclerosis; Inflammation
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-63940DOI: 10.1016/j.bbrc.2010.10.052ISI: 000285071400005OAI: oai:DiVA.org:liu-63940DiVA: diva2:384993
Available from: 2011-01-11 Created: 2011-01-10 Last updated: 2017-12-11

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Theodorsson, Elvar

Search in DiVA

By author/editor
Theodorsson, Elvar
By organisation
Clinical ChemistryFaculty of Health SciencesDepartment of Clinical Chemistry
In the same journal
Biochemical and Biophysical Research Communications - BBRC
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 143 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf